32 results about "Blood vessel remodeling" patented technology

A generally spherical vascular remodeling device is permanently positionable at a junction of afferent and efferent vessels of a bifurcation having an aneurysm. After positioning the device at the junction to substantially conform the device to the shape of the junction, the device acts as a scaffolding to inhibit herniation of objects out of the aneurysm and the device permits perfusion to the efferent vessels. Positioning the device may include deployment and mechanical or electrolytic release from a catheter. Embolic material may be inserted in the aneurysm before or after positioning the device. The device may have a first end, a second end substantially opposite to the first end, and a plurality of filaments extending between and coupled at the first end and the second end. Such devices may be football shaped, pumpkin shaped, or twisted. The device may include a plurality of loops forming a generally spherical shape.

A medical device for implantation into vessels or luminal structures within the body is provided, which stimulates positive blood vessel remodeling. The medical device, such as a stent and a synthetic graft, is provided with a coating with a pharmaceutical composition containing a controlled-release matrix and one or more pharmaceutical substances for direct delivery of drugs to surrounding tissues. The coating on the medical device further comprises one or more barrier layers, and a ligand such as a peptide, an antibody or a small molecule for capturing progenitor endothelial cells in the blood contacting surface of the device for restoring an endothelium at the site of injury. In particular, the drug-coated stents are for use, for example, in balloon angioplasty procedures for preventing or inhibiting restenosis.

A medical device for implantation into vessels or luminal structures within the body is provided, which stimulates positive blood vessel remodeling. The medical device, such as a stent and a synthetic graft, is coated with a pharmaceutical composition consisting of a controlled-release matrix and one or more pharmaceutical substances for direct delivery of drugs to surrounding tissues. The coating on the medical device further comprises a ligand such as a peptide, an antibody or a small molecule for capturing progenitor endothelial cells in the blood contacting surface of the device for restoring an endothelium at the site of injury. In particular, the drug-coated stents are for use, for example, in balloon angioplasty procedures for preventing or inhibiting restenosis.

The invention discloses a cardiotonic capsule for treating chronic heart failure and belongs to the field of traditional Chinese medicines. A preparation method of the cardiotonic capsule comprises the following steps of mixing 3-5 parts by mass of milkvetch root, 3-5 parts by mass of red ginseng, 3-5 parts by mass of prepared monkshood, 2-10 parts by mass of semen lepidii, 3-5 parts by mass of radix ophiopogonis, 2-3 parts by mass of Chinese magnoliavine fruit, 2-3 parts by mass of polygonatum odoratum, 3-5 parts by mass of radix salviae miltiorrhizae, 2-3 parts by mass of ligusticum wallichii, 3-5 parts by mass of kudzuvine root powder, 3-5 parts by mass of radix notoginseng and 3-5 parts by mass of leech, crushing the mixture into fine powder, and filling the fine powder into capsules. The cardiotonic capsule for treating chronic heart failure does not produce any toxic and side effect, is not limited by contraindication, has good effects of treating chronic constrictive and diastolic heart failure, is especially suitable for diastolic heart failure, can improve heart failure symptoms, can correct heart failure pathological and physiological changes, can reverse atherosclerosis, and can improve ischemic myocardial injuries, cardiac muscle and blood vessel remodeling and long-term prognosis of heart failure patients.

The present invention is based on the finding that microRNA from the microRNA gene cluster located on the human chromosomal at locus 14q32 play an important role in vascular development and re-modelling. Modulators of any of the 14q32 microRNA may be exploited as a means to modulate vascular re-modelling processes and / or in the treatment and / or prevention of vascular disorders or disease.

A medical device for implantation into vessels or luminal structures within the body is provided, which stimulates positive blood vessel remodeling. The medical device, such as a stent and a synthetic graft, is provided with a coating with a pharmaceutical composition containing a controlled-release matrix and one or more pharmaceutical substances for direct delivery of drugs to surrounding tissues. The coating on the medical device further comprises one or more barrier layers, and a ligand such as a peptide, an antibody or a small molecule for capturing progenitor endothelial cells in the blood contacting surface of the device for restoring an endothelium at the site of injury. In particular, the drug-coated stents are for use, for example, in balloon angioplasty procedures for preventing or inhibiting restenosis.

The invention discloses a Chinese medicament kudzu-vine root for preventing and treating vascular restenosis, or a medicament composite comprising a kudzu-vine root which serves as a raw material, or the application of extractive which takes the kudzu-vine root as the raw material and serves as an active ingredient in the preparation of a medicament which is used for preventing and treating the vascular restenosis. The invention also discloses a method for preparing the medicament for preventing and treating the vascular restenosis. The Chinese medicament kudzu-vine root for preventing and treating the vascular restenosis is novel medicament application besides the original published medicament effect of the kudzu-vine root. The Chinese medicament kudzu-vine root for preventing and treating the vascular restenosis can obviously improve coronary heart diseases, apoplexy and sequel caused by atherosclerosis, and lumen restenosis caused by newly born endangium after angioplasty and artery scaffold treatment, regulate structural disorder caused by vascular remodeling, and effectively control thrombosis on an injured part and followed thrombus organization. The Chinese medicament kudzu-vine root for preventing and treating the vascular restenosis has the advantages of positive clinical effects, obvious curative effect and quick response, and compared with a scaffold operation and a bypass operation, the Chinese medicament kudzu-vine root also has the advantages of higher safety, lower cost, and more stable and more reliable late result.

A medical device for implantation into vessels or luminal structures within the body is provided, which stimulates positive blood vessel remodeling. The medical device, such as a stent and a synthetic graft, is coated with a pharmaceutical composition consisting of a controlled-release matrix and one or more pharmaceutical substances for direct delivery of drugs to surrounding tissues. The coating on the medical device further comprises a ligand such as a peptide, an antibody or a small molecule for capturing progenitor endothelial cells in the blood contacting surface of the device for restoring an endothelium at the site of injury. In particular, the drug-coated stents are for use, for example, in balloon angioplasty procedures for preventing or inhibiting restenosis.

The present invention is concerned with deuterium-enriched pyrimidine compounds of formula 1, their derivatives and pharmaceutically acceptable salts and methods of use thereoffor the prevention and treatment of neuroendocrine neoplasia including metastasis and fibrosis, fibrotic processes associated with neuroendocrine cell dysregulation for example Crohn's disease, pulmonary arterial hypertension, pulmonary hypertension associated with chronic obstructive pulmonary disease (COPD), right ventricular hypertrophy, pulmonary vascular remodeling, asthma, cystic fibrosis, hypertension, ischemic stroke, angina pectoris, congestive heart failure, arrhythmia, arterial fibrillation, neurodenerative diseases, gastrointestinal disorders , stress disorders, obsessive compulsive disorders, demyelinating diseases, cereberal vascular disorders, bronchoconstriction, vasodilation, smooth muscle contraction, brain disorders, vascular disorders, neuropathological diseases and cardiovascular system regulation.

The invention relates to a three-layer artificial blood vessel electrospinning membrane loaded with micro nucleic acid as well as a preparation method and application thereof. An artificial blood vessel is composed of three electrospinning membranes; an inner membrane is polyethylene glycol-b-poly(L-lactide-co-epsilon-caprolactone)electrospinning fiber membrane and is internally loaded with particles formed by trimethylchitosan-grafted-polyethylene glycol-REDV compound miRNA-126 and PELCL-REDV; a middle membrane is a poly(glycolide-co-lactide)electrospinning fiber membrane and is internally loaded with particles formed by trimethylchitosan-grafted-polyethylene glycol-VAPG compound miRNA-145; and an outer membrane is a poly(epsilon-caprolactone)electrospinning fiber membrane. The three-layer artificial blood vessel is capable of effectively controlling the release rate of two miRNAs; the risk of later-period restenosis during vascular remodeling is reduced; the three-layer artificial blood vessel electrospinning membrane can be applied to the fields of artificial blood vessel materials and blood vessel transplantation biomedical materials.

A medical device for implantation into vessels or luminal structures within the body is provided, which stimulates positive blood vessel remodeling. The medical device, such as a stent and a synthetic graft, is coated with a pharmaceutical composition consisting of a controlled-release matrix and one or more pharmaceutical substances for direct delivery of drugs to surrounding tissues. The coating on the medical device further comprises a ligand such as a peptide, an antibody or a small molecule for capturing progenitor endothelial cells in the blood contacting surface of the device for restoring an endothelium at the site of injury. In particular, the drug-coated stents are for use, for example, in balloon angioplasty procedures for preventing or inhibiting restenosis.

A compound Jiangya capsule for auxiliary treatment of refractory hypertension and its preparation and application, is a preparation process of compound Jiangya capsule for the treatment of hypertension with hyperactivity of liver yang and internal stasis of water, composed of wild chrysanthemum The mixed solution obtained by adding the alcohol extract of medicinal dregs produced after the volatile oil extraction process, the combined water extract of Apocynum apocynum, Morus alba, Sophora japonica, and Prunella vulgaris to the filtrate produced by filtering medicinal dregs in the process of extracting volatile oil from wild chrysanthemum, The alcohol extract and the mixed solution are concentrated, dried and pulverized to obtain two kinds of dry paste powders, mixed with auxiliary material starch to make granules, and then sprayed with volatile oil extracted from wild chrysanthemum and mixed evenly. The compound antihypertensive capsule prepared by the preparation process of the invention can assist western medicine in treating refractory hypertension, regulate blood pressure, protect hypertensive blood vessel remodeling and prevent kidney and other target organ damage.

Pulmonary hypertension is a progressive disease of various origins that is associated with vascular remodelling and results in right heart dysfunction. Accumulating evidence indicates important roles of immune cells and inflammatory chemokines in the pathogenesis and progression of pulmonary hypertension. We have identified CCL21 as anti-remodelling efficacy biomarker for pulmonary hypertension. CCL21 was found to be highly sensitive and specific in discriminating pulmonary hypertension patients from matched controls. CCL21 was upregulated in pulmonary hypertension and down-regulated with treatment with an anti-remodelling agent.

The invention discloses applications of a transcription factor and an oncoprotein-ecotropic viral integration site 1 (EVI-1) inhibitor in vascular remodeling, wherein the EVI-1 inhibitor employs vascular smooth muscle specific marker gene (SMA, SM22, etc) and a specific transcription factor (SRF, Myocardin) as direct target points, thus improving expression of the smooth muscle specific gene, significantly inhibiting conversion from contractile type to secreting type of vascular medial smooth muscle cells, and further reducing abnormal regeneration of inner membrane after vascular injury. Theapplication is carried out from cell functional test into molecular mechanism researching at gene and protein levels, wherein an in-vivo animal pathological model test is converted into specimen analysis of clinical patients; all the results prove that the EVI-1 inhibitor is a key regulation factor for phenotypic transformation of smooth muscle cells; so there are reasons to believe that the EVI-1inhibitor is highly possible to be used as a novel anti-vascular anomaly remodeling medicine for treatment of cardiovascular and cerebrovascular diseases in future.